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Abstract
Background: T-cell immunoglobulin mucin-3 (TIM3) is a TH1-specific type 1 membrane protein
that regulates TH1 proliferation and the development of immunological tolerance. TIM3 and its
genetic variants have been suggested to play a role in regulating allergic diseases. Polymorphisms in
the TIM3 promoter region have been reported to be associated with allergic phenotypes in several
populations. The aims of this study were to examine whether genetic variation in the promoter
region of TIM3 influenced transcription of the gene and risk for allergic phenotypes.
Methods:  We performed 5' rapid amplification of cDNA ends and reverse transcription-
polymerase chain reaction. We screened for polymorphisms in the promoter region. Deletion
analysis was used to localize the promoter region of TIM3. Genotyping was performed by TaqMan
assays in three asthma/allergy population samples.
Results: We found two regions with promoter activity in TIM3. One region was from -214 bp to
+58 bp and the other from -1.6 kb to -914 bp relative to the transcription start site. None of the
single nucleotide polymorphisms (SNPs) or haplotypes affected the transcriptional activity in
reporter gene assays. No association between the SNPs and any phenotype was observed in the
study cohorts.
Conclusion: Our findings indicate that SNPs and haplotypes in the TIM3 promoter region do not
have a functional effect in vitro and are not associated with allergic diseases. These data suggest that
polymorphisms in the TIM3 promoter region are unlikely to play an important role in susceptibility
to allergic diseases.
Background
Asthma is a chronic inflammatory disease of the airways
that is a major cause of morbidity in developed countries
and has been increasing in prevalence [1,2]. Asthma is a
common disease caused by interactions between multiple
genes of small to modest effect and equally important
environmental factors. Asthma susceptibility has been
linked to several loci e.g. chromosomes 5, 6, 11, 12 and 14
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[3]. Among these linkages, chromosome 5q23-35 has
been replicated in several genome-wide studies in differ-
ent populations [3].
McIntire et al. identified a chromosomal region that regu-
lated TH2 cytokine production as well as airway hyperre-
sponsiveness (AHR) using a congenic mouse model of
asthma [4]. This region was distinct from the IL4 cytokine
gene cluster and other nearby cytokine genes [4]. The
region is homologous to human chromosome 5q33 and
contains the TIM (T cell immunoglobulin domain and
mucin domain) gene family [4]. There are two genes in
this family (TIM1 and TIM3) that are biologically plausi-
ble atopy susceptibility genes. TIM1 (also known as the
hepatitis A virus cellular receptor, HAVCR1) is expressed
preferentially on TH2 cells and TIM3  (HAVCR2) is
expressed preferentially on TH1 cells after activation of
naive CD4+ T-helper cells. TH1 cells mediate immune
responses to intracellular pathogens, delayed-type hyper-
sensitivity reactions, and produce cytokines such as inter-
feron-γ, IL2, tumour-necrosis factor-α and lymphotoxin.
TH2 cells mediate immune responses to extracellular path-
ogens and produce cytokines such as IL4, IL10 and IL13
which promote atopic and allergic diseases [5]. TIM1 pro-
motes TH2 cytokine production and proliferation. In a
murine model of asthma, stimulation of TIM1 in the pres-
ence of antigen prevented the development of respiratory
tolerance and increased pulmonary inflammation [6].
TIM3 inhibits TH1-mediated auto- and alloimmune
responses and acts via its ligand, galectin-9, to induce cell
death in TH1 but not TH2 cells [7-9]. Considering their
immunological function and chromosomal location both
TIM1 and TIM3 are good candidate genes for asthma.
Recent association studies suggested that polymorphisms
in the TIM3  promoter region may be associated with
asthma-related phenotypes in both Caucasian and Asian
population samples [10-12]. Other studies have demon-
strated associations of TIM1 polymorphisms with asthma
and related traits [11,13,14]. In the present study, we per-
formed an association study in three asthma/allergy pop-
ulation samples to investigate the role of polymorphisms
in the TIM3  promoter region and determined whether
these polymorphisms affected TIM3 transcriptional activ-
ity.
Methods
Study populations
We used three independent asthma/allergy population
samples: the Canadian Asthma Primary Prevention Study
(CAPPS) cohort, the Study of Asthma Genes and the Envi-
ronment (SAGE) birth cohort and the Saguenay-Lac-St-
Jean (SLSJ)/Québec City (QC) Familial Collection (Table
1). The study protocols were approved by ethical review
boards at all participating institutions. Informed consent
was obtained from each individual or his/her guardian.
The CAPPS cohort was initiated in 1995 and recruited
from two Canadian cites, Vancouver and Winnipeg
[15,16]. Infants were recruited who were at high risk for
the development of asthma, defined as those who had at
least one first-degree relative with asthma or two first-
degree relatives with other allergic diseases. In total, there
were 545 families recruited into this study (549 infants, 4
sets of twins). At the 7-year time point loss to follow-up
was minimal, with 86% of the families completing a ques-
tionnaire. Spirometry and methacholine challenge testing
were performed at the 7-year time point. The diagnoses of
asthma and other atopic disorders were made by a pediat-
ric allergist based on a detailed history and physical exam-
ination. Atopy was defined as at least one positive skin
prick test. Methacholine challenge testing was carried out
according to Cockcroft et al. [17]. The provocative concen-
tration of methacholine that induced a 20% decrease in
FEV1 from post-saline value (PC20) was determined. AHR
Table 1: Sample sizes by study, phenotype and ethnic 
background
Cohorts
CAPPS SAGE SLSJ/QC Combined
Families 545 723 306 1573
Genotyped 1316 1466 1234 4016
Caucasian Samples (complete trios)
Phenotype
Asthma 51 109 379 539
Atopy 105 145 362 612
AHR 142 96 278 516
Atopic Asthma 37 71 305 413
Non Caucasian Samplesa(complete trios)
Asthma 3 28 na 31
Atopy 18 44 na 62
AHR 14 22 na 36
Atopic Asthma 3 20 na 23
Combined Analysisb (complete trios)
Asthma 57 139 379 575
Atopy 135 190 362 687
AHR 170 120 278 568
Atopic Asthma 43 92 305 440
aNon Caucasian samples included individuals of Asian (Chinese, 
Korean and Japanese) and Canadian First Nations descent.
bCombined Analysis also contains trios with mixed and unknown 
ethnicity
CAPPS – Canadian Asthma Primary Prevention Study Cohort; SAGE 
– Study of Asthma Genes and the Environment birth cohort; SLSJ/QC 
– Saguenay – Lac-St-Jean/Québec City Familial Collection; AHR – 
airway hyperresponsivenessBMC Medical Genetics 2009, 10:62 http://www.biomedcentral.com/1471-2350/10/62
Page 3 of 10
(page number not for citation purposes)
for this cohort and the SAGE cohort was defined as a PC20
of less than 3.2 mg/ml methacholine [18,19].
SAGE is a population-based sample of 16,320 children,
born in the province of Manitoba, Canada in 1995 [20].
In 2002, the families were sent a questionnaire to deter-
mine their health and home environment exposure. Chil-
dren were classified according to the presence of asthma
(n = 392), hay fever/food allergy (n = 192) or neither (n =
3002). All the children in the asthma and allergy groups
were invited to participate in the study, together with a
random sample (n = 200) of children with neither condi-
tion. A pediatric allergist assessed the presence of asthma
based on a detailed history and physical examination, a
methacholine challenge test was administered and skin
prick tests for common allergens were performed. In total,
725 families were recruited into the study, including 247
with an asthmatic child and 328 with an atopic child.
The SLSJ/QC Familial Collection is comprised of 306 fam-
ilies from the Saguenay-Lac-Saint-Jean (n = 227) and
Québec City (n = 79) regions of Québec, Canada [21,22].
There is at least one adult asthmatic proband in each fam-
ily. Asthma was assessed using a respiratory health ques-
tionnaire and pulmonary function tests. AHR was defined
as a PC20 < 8 mg/ml at the time of recruitment. If PC20 was
not measurable, a 15% increase in FEV1 after inhalation of
a bronchodilator or a variation in PEF of at least 12%
within a 2-week period was also considered diagnostic of
AHR. Participants were defined as having asthma if they
had a reported history of asthma that was validated by a
physician, or they showed asthma-related symptoms and
a positive PC20 at the time of recruitment. Subjects were
defined as atopic if they had at least one positive response
to a skin prick test. Subjects with a PC20 > 8 mg/ml were
considered not to have AHR; non-asthmatics were those
who had no history of physician-diagnosed asthma, no
symptoms of asthma and a PC20 greater than 8 mg/ml;
non-atopics were those who had no positive response on
skin prick test.
Expression of TIM3 in tissues
The Human Multiple Tissue, Human Immune System
cDNA Panels and Human Blood Fraction Panel (BD Bio-
sciences/Clontech, Palo Alto, CA, USA) were used to ana-
lyze expression of TIM3  in various tissues. The PCR
primers for the gene expression study are listed in Table 2.
Resting CD14+ (monocytes), CD4+ (T helper/inducer
cells), CD8+ (T suppressor/cytotoxic cells) and CD19+ (B
lymphocytes) cells were positively selected from mononu-
clear cells from healthy donors by immunomagnetic sep-
aration with Dynabeads M-450 (Dynal, Oslo, Norway).
Cells were activated with pokeweed mitogen (Invitrogen,
San Diego, CA, USA) and concanavalin A (ICN, Costa
Table 2: Sequence of primers used in reverse transcriptase-polymerase chain reaction, 5' Rapid Amplification of cDNA ends (5'RACE) 
and (RT-PCR) and plasmid constructs
TIM3 RT-PCR primers Forward 5'-tgctgctgctgctactacttaca-3'
Reverse 5'-aggttggccaaagagatgag-3'
5'RACE First round forward 5'-gctggggtgtagaagcagggcagat-3'
First round reverse 5'-ccatcctaatacgactcactatagggc-3'
Nested PCR forward 5'-tgtctgtgtctctgctgggccatgt-3'
Nested PCR reverse 5'-actcactatagggctcgagcggc-3'
Plasmid constructs primers Common reverse primer 5'-attatctcgagtggactgggtacttcttccaa
Forward primer +63 bp 5'-attatggtacctgactgtagacctggcagtgtt-3'
Forward primer -241 bp 5'-attatggtaccggacatgctccatttcaggt-3'
Forward primer -452 bp 5'-attatggtacctgaggcttatgctgggagtt-3'
Forward primer -914 bp 5'-attatggtaccaaaccactcagcctgtgagc-3'
Forward primer -1702 bp 5'-attatggtaccgccttgaccaagttcatgct-3'
Forward primer -2220 bp 5'-attatggtaccccagctccctacacacacaa-3'BMC Medical Genetics 2009, 10:62 http://www.biomedcentral.com/1471-2350/10/62
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Mesa, CA, USA) by standard methods, and the degree of
activation of lymphocytes was estimated on the basis of
morphological criteria (blast morphology and mitoses)
and expression of two activation markers, CD25 (inter-
leukin-2 receptor) and CD71 (transferrin receptor). We
used glycerol-3-phosphate dehydrogenase (G3PDH) as an
internal control for PCR. Amplification conditions were
an initial denaturation step at 94°C for 10 min followed
by 34, and 30 cycles of denaturation at 94°C for 30 s,
annealing at 60°C for 30 s and extension at 72°C for 30 s
for primer pairs amplifying TIM3  and  G3PDH, respec-
tively.
5' Rapid Amplification of cDNA ends (5'RACE)
We performed 5' RACE experiments using commercially
available RACE-ready human leukocyte and spleen
cDNAs (Marathon Ready cDNA, BD Biosciences/Clon-
tech) according to the manufacturer's instructions. Prim-
ers used for amplification for the first round PCR and for
the nested PCR are shown in Table 2. The amplified RACE
product was cloned into pCR2.1 TOPO-TA cloning vector
(Invitrogen). Plasmids were purified by column chroma-
tography (Invisorb Spin Plasmid Mini Kit, Invitek GmbH,
Berlin) and subjected to direct sequencing with M13
primers.
Single nucleotide polymorphism (SNP) screening and 
genotyping
Approximately 2500 bp of the 5' flanking region upstream
of the transcription initiation site of TIM3 was amplified
by PCR from genomic DNA of 19 unrelated healthy Cau-
casians. Subsequently, the products were subjected to
direct sequencing with a Big-Dye Terminator Kit (Applied
Biosystems, Foster City, CA, USA). Genotyping of the two
tag SNPs was done by TaqMan Assay-on-Demand™ SNP
typing (Applied Biosystems).
Plasmid construction, transfection and luciferase assay
Genomic fragments of the 5' flanking region of exon 1 of
TIM3 were amplified. PCR products were digested with
XhoI and KpnI overnight at 37°C and then subcloned into
the pGL3-Basic vector (Promega, Madison, WI, USA)
digested with XhoI and KpnI. The clones were sequenced
to confirm that the inserts were correct. The YT human T/
NK cell line provided by Dr. Zacharie Brahmi as a gift was
resuspended in RPMI 1640 (Sigma-Aldrich Co, St. Louis,
MO, USA) with 20% FBS. Approximately 1 × 107 YT cells
were cotransfected with 30 μg of test construct and 150 ng
of pPL-TK (Promega) by electroporation with a Gene Pul-
sar II (Bio-Rad, Hercules, CA) set at 300 V and 975 μF.
Transfected cells were harvested 24 h after transfection.
Cells were lysed by the addition of 200 μl of lysis buffer
(Promega). Twenty μl of each lysate was used for luci-
ferase assay with the Dual-Luciferase Reporter Assay Sys-
tem (Promega). The firefly luciferase values were
normalized to the Renilla  luciferase values of pRL-TK,
which were determined at the same time. The signal was
read using a POLARstar OPTIMA (BMG, Alexandria, VA,
USA) fluorimeter. Reporter activity is presented as the
mean of at least five independent measurements.
Statistical analysis
Differences in transcriptional activity in the reporter gene
assays were analyzed by ANOVA and unpaired t-tests. We
tested for association with asthma, atopy, atopic asthma
and airway hyper- responsiveness phenotypes using the
Family based Association Test (FBAT) software [23].
Results
Tissue expression of TIM3
Expression of TIM3 was analyzed by PCR-based methods
(Figure 1). TIM3 was strongly expressed in placenta, lung,
kidney, spleen, and leukocytes. In the Human Blood Frac-
tion Panel TIM3  was more highly expressed in active
CD4+ cells than resting CD4+ cells. However it was more
highly expressed in resting CD8+ cells than in active CD8+
cells. TIM3 was also strongly expressed in resting CD14+
cells. No splicing variants were found.
Isolation of 5' full-length TIM3 transcripts and structure of 
the human TIM3 gene
Current information at the time of the experiment (Janu-
ary 2007) in the NCBI database http://
www.ncbi.nlm.nih.gov indicated that TIM3  was com-
posed of seven exons and the translational start site was
contained within exon 1. TIM3 was highly expressed in
leukocytes and spleen and therefore 5' RACE experiments
were performed with cDNAs derived from these cell types.
We were able to identify an additional 25 bp of sequence
on the 5' side of the known cDNA sequence (Figure 2). No
additional novel exons were detected.
Polymorphism screen
We screened for polymorphisms in the TIM3 promoter
region using DNA from 19 unrelated normal subjects and
found six polymorphisms -574 G/T (rs10515746), -882
C/T (rs4704853), -1516 G/T (rs10053538), -1571delC, -
1766G/T (rs10061463) and -1922 G/A (rs12186731) in
TIM3 (Figure 2). Among the six polymorphisms four (-
574 G/T, -882 C/T, -1571delC and -1766G/T) were in per-
fect linkage disequilibrium (r2 = 1). There were only three
haplotypes formed by the six polymorphisms.
Transcriptional activity of the 5' flanking region of TIM3
To examine the transcriptional activity in the 5' flanking
region of TIM3, we constructed plasmids that contained
sequences from -2220, -1702, -914, -452, -241 and +63 rel-
ative to the transcription initiation site. The primers used
for plasmid construction are listed in Table 2. The expres-
sion of TIM3 in YT cells was confirmed by RT-PCR (data not
shown). The constructs were then transiently transfected
into YT cells. Deletion analysis revealed that promoterBMC Medical Genetics 2009, 10:62 http://www.biomedcentral.com/1471-2350/10/62
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Expression of TIM3 in multiple human tissues Figure 1
Expression of TIM3 in multiple human tissues. Results of PCR amplification of cDNA from different organs (A), the 
immune system (B), and blood fractions (C) are shown. G3PDH was included as an internal control. MC, mononuclear cells; R, 
resting; A, activated; NC, non-template control.
Genomic structure of the human TIM3 gene Figure 2
Genomic structure of the human TIM3 gene. The open boxes represent the positions of exons 1–7. The shaded box is 
the region we extended in our 5'RACE experiment. TIM3 contains seven exons and the coding sequence (CDS) starts in exon 
1. The downward arrows indicate the SNPs in the promoter region. The four red arrows indicate SNPs that are in perfect LD.BMC Medical Genetics 2009, 10:62 http://www.biomedcentral.com/1471-2350/10/62
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activity of TIM3  in YT cells required at least 241 bp of
upstream sequence and the maximal reporter gene expres-
sion was observed with the -1702 bp construct (Figure 3).
There were five polymorphisms, -574 G/T, -882 C/T, -1516
G/T, -1571delC and -1766G/T in this region. To determine
whether the five polymorphisms and their haplotypes were
functional, we generated luciferase reporter gene constructs
that contained the 5' flanking region of TIM3 from exon 1
to -1702 bp with three different haplotypes, i.e., haplotype
GCGCG, haplotype GCTCG and haplotype TTG-T. The
results showed there was no difference in expression level
between each haplotype (Figure 3).
FBAT analysis
To determine whether the previously reported TIM3 associ-
ations [10-12] were present in the CAPPS, SAGE and SLSJ/
QC populations, we chose -882 C/T and -1922 G/A as tag
SNPs. However -1922 G/A was in a region of repetitive
sequence. Therefore, rs13170556, which was in perfect
linkage disequilibrium (LD) with -1922 G/A, was geno-
typed in our samples. Both polymorphisms (rs13170556
and rs10061463) were in Hardy-Weinberg equilibrium (p
> 0.1) in all cohorts. We performed FBAT analysis to test for
association with asthma, atopy, atopic asthma and AHR.
The results were corrected by the number of SNPs tested
within TIM3 (n = 2) and the effective number of independ-
ent phenotypes (n = 3). We found that rs13170556 was
associated with asthma in the CAPPS cohort in both the
Caucasians only analysis and in the combined analysis of
the Caucasian families with the non Caucasian families (p
= 0.0138 and 0.0085, respectively) (Table 3). However,
after correction for multiple testing we found no evidence
for association in any of the three cohorts individually or in
joint analysis of all the cohorts (Table 3). Similarly, there
was no association found for -882C/T with any phenotype
in any of the analyses (Table 4).
Discussion
In the present study, we determined the expression pat-
tern of TIM3 in human cells. We investigated the genomic
structure and transcriptional activity of TIM3 and investi-
gated polymorphisms in the promoter region of TIM3 in
multiple cohorts. We isolated the full-length genomic
region of TIM3 and characterized its promoter region. We
found six polymorphisms in TIM3, but none was associ-
ated with asthma or the transcriptional activity of the gene
in vitro.
TIM3  was initially cloned as a TH1-specific cell-surface
marker. In our results, TIM3 was expressed on activated
CD4+ cells as well as resting CD8+ cells and CD14+ cells,
consistent with previous reports. In the mouse, TIM3 was
expressed in both CD4+ and CD8+ cells [24,25] and in
human peripheral blood mononuclear cells TIM3  was
expressed at a higher level on CD14+ cells and CD8+ cells
than on CD4+ cells [26]. TIM3 was also reported to be
expressed in NK and NTK (NK-like T) cells [26,27]. In our
results, TIM3 was expressed at a higher level in activated
CD4+ cells than in resting CD4+ cells but conversely
expression was higher in resting CD8+ than in activated
CD8+ cells. Our results demonstrate that the expression
level of TIM3 is not only differentially regulated in subsets
of T cells but is also determined by the activation state of
the cell.
TIM3 is expressed in human NK cells both at the mRNA
and protein levels [26,27]. We found that TIM3 was also
expressed in one type of NK cell line, the YT cell line,
which was used in the reporter gene assays. We identified
TIM3  promoter activity in the -241 bp and -1702 kb
regions relative to the transcription initiation site. Con-
served non-coding sequences may contain transcriptional
regulatory elements participating in the temporal and tis-
sue-specific expression patterns of genes [28,29]. In the
UCSC website http://genome.ucsc.edu/ there are three
conserved regions in the TIM3 promoter (Figure 3B) and
the first conserved region contributes to the -241 bp pro-
moter region and the last two regions contribute to the -
1702 bp promoter region. There are five SNPs in the -1.7
kb region and the -1516 G/T, -1571delC and -1766G/T
SNPs flank the conserved sequence. However, the haplo-
type formed by these SNPs did not affect the promoter
activity (Figure 3C). We also stimulated the YT cell line
with IL-2 at different concentrations but we found no dif-
ference in promoter activity among the different haplo-
types after the stimulation (data not shown).
There are discrepant reports concerning the association
between TIM3 polymorphisms and allergic phenotypes
[10-14]. Graves et al. [11] studied a mixed Caucasian/His-
panic population. The two TIM3 SNPs that showed asso-
ciation with eczema and atopy were rs1036199 and
rs4704853. However, in our sample these two SNPs were
in perfect LD and rs4704853 was not associated with any
phenotype. This discrepancy may be due to the different
ethnic group studied in the previous report [11]. Two
other studies reported associations in Asian samples
[10,12]. The -574G > T (rs10515746) polymorphism was
associated with asthma and rhinitis in a Korean popula-
tion although the -574T allele was found in less than 2%
of the patients [10]. Therefore, our study may not have
been adequately powered if this association is limited to
the Asian population.
In Caucasian and African-American populations no asso-
ciation of TIM3 polymorphisms was seen with asthma or
related phenotypes [13,14]. The three cohorts used in this
study were family-based and there were more than 1000
individuals in each cohort. There were non-Caucasian
samples in both SAGE and CAPPS but we analyzed the
data separately to avoid possible loss of power due to
genetic heterogeneity. Correction for multiple compari-BMC Medical Genetics 2009, 10:62 http://www.biomedcentral.com/1471-2350/10/62
Page 7 of 10
(page number not for citation purposes)
Promoter activity assay of the human TIM3 gene promoter constructs Figure 3
Promoter activity assay of the human TIM3 gene promoter constructs. (A) Luciferase activity is presented relative to 
the PGL3 basic vector after each construct was transfected into YT cells. All values are the mean ± SD of at least five inde-
pendent experiments. (B) Comparison of the promoter activity and the conserved regions in the human genome. (C) Compar-
ison of the promoter activity between the haplotypes.BMC Medical Genetics 2009, 10:62 http://www.biomedcentral.com/1471-2350/10/62
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sons was performed to avoid false positive results.
Although a nominal association of rs13170556 was
found in the CAPPS cohort it was not significant after cor-
rection for multiple comparisons. Moreover, the associa-
tion was not replicated in the other two cohorts and in the
combined analysis of all three cohorts. Therefore, the
association was likely a statistical artifact rather than a true
positive result.
We did not analyze other phenotypes such as total or spe-
cific serum IgE in this study. We did not analyze haplo-
types in the patient cohorts as we believe that this would
have been inappropriate since we used tag SNPs from
HapMap and it has been suggested that in this scenario
there is little benefit of exhaustive haplotype testing [30].
In addition, we used the most powerful approach given
our study design, there is high LD in the region, the
marker coverage was not dense and our single SNP main
effects were negative. All these factors made it unlikely
that we would have benefited from haplotype tests.
The power to detect an association in this study varied
with the phenotype, allele frequency and cohort consid-
ered. Power was calculated using the TDT Power Calcula-
tor [31]. For a major allele 'A' and minor allele 'a', we
assumed the penetrance of the three genotypes was AA =
0.1, Aa = 0.2 and aa = 0.5. For an allele frequency of 0.13
and the phenotype of allergic asthma in the CAPPS cohort
Table 3: Allele frequencies of the rs13170556 polymorphism in the three study cohorts for each phenotype
Cohort Phenotype Caucasian only Combined analysisa
Frequency OR p cpc Frequency OR p cpc
CAPPS Asthma 0.13 0.31 0.0138 0.0822 0.13 0.29 0.0085 0.0508
Atopy 0.73 0.3294 1.0000 0.62 0.1070 0.6359
AHR 0.90 0.7455 1.0000 0.86 0.6393 1.0000
Atopic Asthma 0.40 0.1031 0.6127 0.36 0.0653 0.3882
SAGE Asthma 0.18 1.60 0.1477 0.8707 0.17 1.30 0.3757 1.0000
Atopy 1.11 0.6961 1.0000 1.06 0.8084 1.0000
AHR 1.33 0.3972 1.0000 1.15 0.6472 1.0000
Atopic Asthma 1.80 0.1279 0.7540 1.43 0.3022 1.0000
SLSJ/QC Asthma 0.15 0.95 0.7456 1.0000 0.15 0.95 0.7456 1.0000
Atopy 0.86 0.3669 1.0000 0.86 0.3669 1.0000
AHR 0.71 0.0749 0.4350 0.71 0.0749 0.4350
Atopic Asthma 0.88 0.4758 1.0000 0.88 0.4758 1.0000
Combined analysisb Asthma 0.15 0.94 0.6802 1.0000 0.15 0.91 0.5001 1.0000
Atopy 0.89 0.3718 1.0000 0.86 0.2179 1.0000
AHR 0.84 0.2402 1.0000 0.83 0.1775 1.0000
Atopic Asthma 0.93 0.6434 1.0000 0.90 0.4961 1.0000
aCombined analysis of the Caucasian families with the non Caucasian families
bCombined analysis of the three cohorts (CAPPS, SAGE and SLSJ/QC)
ccorrected p value
CAPPS – Canadian Asthma Primary Prevention Study Cohort; SAGE – Study of Asthma Genes and the Environment birth cohort; SLSJ/QC – 
Saguenay – Lac-St-Jean (SLSJ)/Québec City (QC) Familial Collection; AHR – airway hyperresponsivenessBMC Medical Genetics 2009, 10:62 http://www.biomedcentral.com/1471-2350/10/62
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(i.e. 37 trios) the power to detect an association was only
0.41. However, for a sample size of 96 trios (e.g. AHR in
the SAGE cohort) the power was 0.80 and was >0.80 for
all other phenotypes in all cohorts in the Caucasians.
Conclusion
Our findings indicate that SNPs and haplotypes in the
TIM3 promoter region do not have a functional effect in
vitro and are not associated with allergic diseases. These
data suggest that polymorphisms in the TIM3 promoter
region are unlikely to play an important role in suscepti-
bility to allergic diseases.
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AHR 0.87 0.5528 1.0000 0.86 0.4967 1.0000
Atopic Asthma 0.55 0.2218 1.0000 0.73 0.4904 1.0000
SAGE Asthma 0.17 1.10 0.7576 1.0000 0.15 1.13 0.6743 1.0000
Atopy 1.18 0.5635 1.0000 1.14 0.6113 1.0000
AHR 1.25 0.5045 1.0000 1.10 0.7576 1.0000
Atopic Asthma 1.36 0.4319 1.0000 1.33 0.3972 1.0000
SLSJ/QC Asthma 0.25 0.97 0.7902 1.0000 0.25 0.97 0.7902 1.0000
Atopy 1.03 0.8263 1.0000 1.03 0.8263 1.0000
AHR 1.12 0.4232 1.0000 1.12 0.4232 1.0000
Atopic Asthma 1.00 1.0000 1.0000 1.00 1.0000 1.0000
Combined analysisb Asthma 0.20 0.97 0.8149 1.0000 0.18 0.99 0.9542 1.0000
Atopy 1.01 0.9526 1.0000 1.01 0.9542 1.0000
AHR 1.07 0.5610 1.0000 1.05 0.6904 1.0000
Atopic Asthma 0.99 0.9454 1.0000 1.02 0.8937 1.0000
aCombined analysis of the Caucasian families with the non Caucasian families
bCombined analysis of the three cohorts (CAPPS, SAGE and SLSJ/QC)
ccorrected p value
CAPPS – Canadian Asthma Primary Prevention Study Cohort; SAGE – Study of Asthma Genes and the Environment birth cohort; SLSJ/QC – 
Saguenay – Lac-St-Jean (SLSJ)/Québec City (QC) Familial Collection; AHR – airway hyperresponsivenessBMC Medical Genetics 2009, 10:62 http://www.biomedcentral.com/1471-2350/10/62
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